Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant crisantaspase - Jazz Pharmaceuticals/Primrose Bio

Drug Profile

Recombinant crisantaspase - Jazz Pharmaceuticals/Primrose Bio

Alternative Names: Asparaginase Erwinia chrysanthemi (recombinant)-rywn; Asparaginase Erwinia chrysanthemi-rywn; Enrylaze; JZP-458; PF-743; Recombinant Asparginase Erwinia chrysanthemi - Jazz Pharmaceuticals/Primrose Bio; Recombinant Erwinia asparaginase - Jazz Pharmaceuticals/Primrose Bio; Rylaze

Latest Information Update: 13 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfenex
  • Developer Jazz Pharmaceuticals plc
  • Class Amidohydrolases; Antineoplastics; Cytostatics; Recombinant proteins
  • Mechanism of Action Asparaginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 31 May 2024 Updated adverse events data from a phase II/III trial in Precursor cell lymphoblastic leukaemia presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 09 Dec 2023 Efficacy, adverse events and pharmacokinetics datafrom a phase II/III trial in Precursor cell lymphoblastic leukaemia-presented at 65th American Society of Hematology Annual Meeting and Exposition 2023 (ASH-Hem-2023)
  • 22 Sep 2023 Registered for Precursor cell lymphoblastic leukaemia-lymphoma (In infants, In adolescents, In children, In adults, Combination therapy) in European Union, Iceland, Norway, Liechtenstein
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top